Tregalizumab
Tregalizumab is a monoclonal antibody designed for the treatment of autoimmune diseases. It is a humanized antibody that binds to the CD4 receptor on certain T cells. It was developed by Biotest.
Mechanism of action[edit]
Tregalizumab binds to a specific site on the CD4 receptor that is only exposed on regulatory T cells (Tregs). This binding enhances the suppressive function of Tregs, which in turn reduces the activity of effector T cells, the cells that cause damage in autoimmune diseases.
Clinical trials[edit]
Tregalizumab has been tested in several clinical trials. In a phase II trial for rheumatoid arthritis, it showed a trend towards efficacy but did not meet its primary endpoint. Further development for this indication was therefore halted. However, it is still being investigated for other autoimmune diseases.
References[edit]
See also[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
